People

The People

Elevance earns a B+ for governance: textbook-strong board practices (independent chair, 11/12 independent directors, robust clawback, no hedging or pledging, meaningful stock-ownership requirements) paired with credible alignment — CEO Gail Boudreaux personally owns roughly $126M of stock and bought another $2.4M on the open market in mid-2025 after the stock had sold off. The main blemishes are a classified board structure (BCBSA-mandated, not chosen) and a 2024 selling spike where Boudreaux personally cashed out approximately $17M near the share-price peak.

The People Running This Company

The reader needs to trust five operators. Boudreaux is the only one with line-CEO experience at a big-three managed-care peer; the others are functional leads. Mark Kaye is the most consequential recent hire — UnitedHealth's UMR/Optum disclosures and Medicaid acuity remediation will land on his desk first.

Boudreaux is the strongest credential on the page. She ran UnitedHealthcare (the operating subsidiary, not the parent) from 2011-2014 and has been at Elevance since 2017 through the WellPoint-to-Anthem-to-Elevance rebrand and the Carelon build-out. Her tenure spans one of the better total-shareholder-return runs among the big-five managed-care peers (2017-2023), though the past 24 months have erased much of that lead.

Kaye is the wild card. He came from MFS Investment Management — an asset manager, not a healthcare insurer — in September 2023, with a $2.5M cash sign-on bonus that vests over three years (repayable on early voluntary exit). He has no managed-care P&L history; his contribution will be judged on Medicaid pricing discipline and the 2026 EPS rebase to "at least $25.50" he and Boudreaux just walked the Street to.

Haytaian, Norwood, Kendrick are operating heads. All are retirement-eligible under the LTIP; succession risk inside the bench is real — Norwood's expanded Feb-2026 mandate (now Chief Health Benefits Officer over both Government and Commercial) consolidates two prior NEO seats and looks like a tournament for COO/successor.

What They Get Paid

The 2025 pay-for-performance link works. Boudreaux's "Compensation Actually Paid" — the SEC-mandated mark-to-market measure — collapsed to negative $3.96M in 2024 when the stock cratered, then rebounded to $18.8M in 2025 as the stock partially recovered. This is the formula doing what it should.

The shape is sensible. Boudreaux's package is 79% equity (PSUs + RSUs + options) with a three-year PSU performance window tied to Adjusted EPS and Operating Revenue. Annual cash AIP paid out at 86.5% of target for 2025 — the lowest payout ratio in three years and consistent with a tougher operating result. The $22.6M headline is high in absolute terms (CEO pay ratio is 286:1 against a $79K median employee) but tracks the median for a top-10 S&P 500 healthcare insurer; UNH and CI CEOs are in the same zip code. Say-on-pay drew 92% support in 2025 — no shareholder revolt.

The one watch-item is the negative-CAP year. In 2024, the value of unvested equity outstanding actually fell more than what was newly granted, producing the unusual -$3.96M line. That is the compensation framework working — but it is also a reminder that "headline pay" of $20-22M each year is a gross figure, not net of mark-to-market.

Are They Aligned?

This is the section where governance reports usually struggle for a non-founder, non-promoter US large-cap. For Elevance, the answer is "yes, but not because anyone is forced to be." Boudreaux exceeds her 6x-salary stock requirement by a multiple of 13. The 2025 capital-return record is shareholder-friendly — $4.1B returned, of which $2.6B was buybacks — and management has committed to another $2.3B of repurchases in 2026 against a downgraded earnings base.

The insider tape tells a clear story:

• 2024 was an aggressive selling year. $44.2M of open-market sales by insiders — Boudreaux personally took $17M off the table in a single July 2024 day at ~$500/share, just before the stock began its 12-month, ~40% slide. Norwood sold $10.8M in April 2024; Haytaian sold $10.6M in March 2024.
• 2025-2026 has been a mild-positive turn. Boudreaux purchased $2.4M of shares on the open market in July 2025 at ~$290 — roughly 40% below where she had been a seller. Director Steven Collis bought $870K in March 2026 at $290. Director Susan DeVore added $375K in August 2025. Five open-market purchases by four insiders in 18 months is unusual for a megacap insurer.
• No pledges, no hedges, no margin loans. Insider trading policy explicitly bans all three for directors and designated associates including all NEOs. The stock-ownership guideline (CEO 6x salary, EVPs 3x) is met by every NEO and binds by requiring 100% retention of net-of-tax vesting until met.
• Dilution is not a problem. Total directors+executive officers (19 people) own only 0.34% of the company, so insider grants — even substantial ones — barely register against a 232.6M share count. The board is genuinely returning capital: 2025 share count fell ~3% from buybacks.
• No related-party drama. The proxy's standing related-party policy ($120K threshold) ratified all 2025 transactions as ordinary-course, arm's-length. No NEO family employment, no founder-controlled supplier, no whitelabel deals with director-affiliated entities. For a $175B-revenue health-insurance holding company, this is the absence of a story.

Board Quality

Eleven of twelve directors are independent. The Audit, Compensation, Finance and Governance committees are 100% independent. Average tenure is 8.3 years — neither stale nor green. The board has been refreshed twice in the past 18 months: Steven Collis (former Cencora CEO) joined in 2025 and Amy Schulman (Polaris Partners managing partner, ex-Pfizer GC) joined in January 2026. The mandatory retirement age of 73 is being enforced — Kerry Clark steps off in May 2026 and is not eligible for re-election.

The board's strongest feature is the healthcare-and-regulation density of its independent directors. Schulman (biotech VC, ex-Pfizer GC), Collis (ex-Cencora — pharma distribution, the other side of the prescription-benefits trade), Jallal (Immunocore CEO) and DeVore (ex-Premier Inc. CEO — hospital GPO) collectively cover the entire pharma–provider supply chain that Carelon and CarelonRx are trying to disintermediate. That is a strategic board, not a compliance board.

The structural weaknesses worth naming:

• Classified board (three classes, three-year terms). Imposed by the BCBSA Blue Cross Blue Shield licensing agreement, not chosen — but it still entrenches incumbents and weakens annual accountability. The proxy commits to declassifying if BCBSA ever drops the requirement.
• Tenure outliers. Peru (independent chair) is 22 years tenured and Dixon is 15. Both are within five years of mandatory retirement, so the issue self-resolves.
• No financial expert is also a current insurance executive. Strable (Principal Financial CEO) is the closest proxy but Principal is a financial-services firm, not a managed-care insurer.

The Verdict

Grade: B+. The strongest positive is honest alignment — Boudreaux personally bought $2.4M of stock on the open market in July 2025 at prices 40% below where she sold in mid-2024, holds ~$126M of equity exposure, and runs a board that has demonstrably refreshed itself and policed its own independence. The compensation framework is doing real work: -$3.96M of "compensation actually paid" in 2024 is exactly the disincentive a stock-linked plan should produce when shareholders lose money.

The two real concerns are (1) the 2024 selling spike by NEOs near the share-price peak — clean under 10b5-1 but still uncomfortable given the 2025 earnings reset that followed, and (2) operational succession: three of the four operating-EVPs are retirement-eligible, and the next CFO has 30 months in seat with no managed-care P&L track record. Neither is a sell signal, but both are reasons to watch the next two annual incentive payouts and the next Form 4 cluster carefully.

Most likely upgrade trigger: A clean 2026-2027 EPS execution against the new $25.50 baseline with continued buyback discipline, plus visible internal succession (a named COO from inside the EVP bench) would push this to A-. Most likely downgrade trigger: Another quarter of insider selling clustered above $325, or any clawback action triggered by a 2026 restatement, would knock it to B.